By Editorial TeamDigital health is finally growing up. For years, venture-backed platforms were valued on fuzzy metrics like user engagement and acquisition numbers. But the real customers, health systems, employers, and health plans, are tired of paying for clicks and want to see an actual return on investment. This means hard clinical outcomes are now the only currency that matters. Investors have to learn to tell the difference between a slick marketing app and a genuine clinical tool that has the peer-reviewed data to back it up.
Clinical Validation is Essential
With a million AI health tools out there, just having a cool algorithm isn’t enough. You have to prove it works. That’s table stakes now for getting and keeping investor money. If you’re building an AI platform for, say, chronic disease, you’re going to get asked for hard proof that your tech actually improves a patient’s health. We’re not talking about self-reported surveys or happy customer quotes. We’re talking about the gold standard: randomized controlled trials (RCTs). For any investor doing their homework, checking for published RCTs is step one. Take a diabetes management app. I want to see a peer-reviewed study showing your platform caused a significant, lasting drop in patients’ HbA1c levels. Without that kind of evidence, all you have is a pretty UI and a prayer. The FDA agrees, and their FDA SaMD guidance on clinical evidence makes it clear you need solid clinical data if you’re making medical claims.
Benchmarking Against Industry Leaders: Omada Health vs. Teladoc/Livongo
To see how this works in practice, just look at how some of the big players in chronic care management stack up on clinical validation.
Omada Health’s Clinical Evidence Pipeline
Omada Health is a good example of doing this right. From the beginning, their entire strategy has been built around publishing peer-reviewed research, especially for type 2 diabetes. If I were evaluating Omada, I’d immediately search for their RCTs in places like the Journal of Medical Internet Research (JMIR). I’m looking for the nitty-gritty details in those studies, methodology, who the participants were, and what the intervention actually was. Most importantly, I need to see statistically significant drops in hard clinical numbers like HbA1c, weight, or blood pressure. For instance, their Digital Diabetes Prevention Program has published RCT data showing it works for HbA1c reduction and weight loss. This is the kind of stuff that shows they’re building a real medical intervention, not just an engagement-farming app. It’s a huge positive signal.
Teladoc Health and Livongo’s Integrated Approach
When Teladoc Health bought Livongo back in October 2020, it created a behemoth in chronic care. Before the deal, Livongo was also focused on clinical proof, but they often framed it around cost savings to get employers and health plans on board, showing how their platform improved blood glucose control and lowered average HbA1c. Now that they’re one company, the challenge is to prove their value across a much wider range of diseases. An investor looking at the combined Teladoc/Livongo today should be asking: where are the new RCTs for all these other conditions you’ve bundled together? They need to show they’re still investing in clinical trials and generating real-world evidence (RWE). Having a massive proprietary dataset is one thing, but that data’s only valuable if you use it to produce published studies with demonstrable clinical wins.
The Role of Independent Accreditation: NCQA Standards
Published studies are one thing, but you also need to look for independent stamps of approval. For AI health tools, the big one is accreditation from the National Committee for Quality Assurance (NCQA). NCQA sets the bar for quality in clinical programs, and getting their seal of approval means a digital platform is being held to high standards for patient safety and clinical effectiveness. For any serious investor (growth equity or institutional LPs), checking for NCQA accreditation is a dealbreaker. It’s not optional. Omada provides a great case study here: they became the first fully-virtual provider to get NCQA Population Health Program Accreditation for their Diabetes and Diabetes+Hypertension programs back in 2021, and they’ve already renewed it through 2026. Teladoc Health has some NCQA certifications too, for things like physician credentialing. Seeing that NCQA logo means the company has a real quality management system (QMS) and isn’t just winging it, which builds a ton of trust when they’re trying to get integrated into payer and employer networks. If a company doesn’t have it or isn’t even trying to get it? That’s a huge red flag. It tells me they’re either immature or racking up regulatory debt. You can check the NCQA digital health program recognition criteria yourself.
Strategic Implications for Investment Decisions
So what’s the takeaway for investors? Simple: don’t even think about putting serious money into a digital health AI platform unless it has a pipeline of peer-reviewed clinical evidence. The companies that will win (and deliver big exit multiples) are the ones that build clinical validation into their product from day one, not as a marketing afterthought. Focusing on outcomes is the best way to de-risk an investment because it gives you hard proof that the thing actually works, proof that payers, providers, and patients are all starting to demand. It also makes working through the regulatory maze much easier. If your tool is a Software as a Medical Device (SaMD), you’re going to need strong clinical data for your 510(k) or De Novo submission anyway. A company that’s already investing in generating this evidence isn’t just being responsible, it’s showing it understands how the game is actually played. Look at journals like the Journal of Medical Internet Research (JMIR) – example of peer-reviewed digital health research to see what this evidence looks like in the wild. The days of funding digital health based on engagement metrics are over. As the market gets more sophisticated, investors have to get smarter. That means prioritizing platforms that can prove they work through published RCTs and independent accreditations like NCQA. This isn’t just a “best practice”, it’s the only way to sift through the noise and find the AI health platforms that are actually built to last. It’s how you identify the real performers.
Frequently Asked Questions
What is the primary shift in valuation metrics for digital health platforms that investors are now prioritizing?
The primary shift is from valuing platforms based on engagement metrics, user acquisition, and perceived market traction to prioritizing hard clinical outcomes. Investors are now seeking demonstrable return on investment and evidence that interventions translate into tangible improvements in patient health, moving beyond marketing-driven point solutions.
What type of evidence is considered the ‘gold standard’ for demonstrating clinical efficacy in digital health AI, and why is it crucial?
The gold standard for demonstrating clinical efficacy is randomized controlled trials (RCTs) with published, peer-reviewed results. This is crucial because it provides empirical backing, moving beyond self-reported data or anecdotal success stories, and is a prerequisite for sustained growth and investor confidence, as highlighted by FDA SaMD guidelines.
Beyond peer-reviewed publications, what other independent validation is important for digital health platforms?
Independent accreditation, particularly from organizations like the National Committee for Quality Assurance (NCQA), is important. NCQA accreditation signifies that a program meets high standards for patient safety, quality improvement, and clinical effectiveness, providing an additional layer of trust and accountability for investors.
